For the quarter ended June 2026, Stryker (SYK Quick QuoteSYK - Free Report) reported revenue of $6.59 billion, up 9.4% over the same period last year. EPS came in at $3.69, compared to $3.13 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $6.56 billion, representing a surprise of +0.48%. The company delivered an EPS surprise of +6.65%, with the consensus EPS estimate being $3.46.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Stryker performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales by Geography- International: $1.63 billion versus $1.65 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11% change.
• Net Sales by Geography- United States: $4.96 billion compared to the $4.9 billion average estimate based on two analysts. The reported number represents a change of +8.9% year over year.
• Net Sales by Geography- Orthopaedics: $2.96 billion versus the four-analyst average estimate of $2.96 billion. The reported number represents a year-over-year change of +31.7%.
• Net Sales by Business- MedSurg and Neurotechnology: $3.63 billion versus $3.59 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.9% change.
• Net sales- Orthopaedics - Ortho Tech: $717 million compared to the $723.41 million average estimate based on three analysts.
• Net Sales by Geography- Orthopaedics- Trauma and Extremities: $1.07 billion compared to the $1.05 billion average estimate based on three analysts. The reported number represents a change of +12% year over year.
• Net Sales by Business- MedSurg and Neurotechnology- Instruments: $1 billion compared to the $1.01 billion average estimate based on three analysts. The reported number represents a change of +30.6% year over year.
• Net Sales by Business- MedSurg and Neurotechnology- Endoscopy: $1 billion versus the three-analyst average estimate of $946.68 million. The reported number represents a year-over-year change of +11.7%.
• Net Sales by Business- MedSurg and Neurotechnology- Medical: $1.12 billion compared to the $1.04 billion average estimate based on three analysts. The reported number represents a change of +13.3% year over year.
• Net Sales by Geography- Orthopaedics- Hips: $479 million compared to the $496.9 million average estimate based on three analysts. The reported number represents a change of +2.8% year over year.
• Net Sales by Business- MedSurg and Neurotechnology- Vascular: $496 million versus the three-analyst average estimate of $579.76 million. The reported number represents a year-over-year change of -0.4%.
• Net Sales by Geography- Orthopaedics- Knees: $693 million compared to the $690.28 million average estimate based on three analysts. The reported number represents a change of +8.3% year over year.

View all Key Company Metrics for Stryker here>>>

Shares of Stryker have returned +12.4% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.